Frijlink, prof. dr. Erik
Erik Frijlink (1960, Meppel) is sinds 1998 hoogleraar Farmaceutische Technologie en Biofarmacie aan de Rijksuniversiteit Groningen. Daarvoor was hij hoofd van de afdeling Farmaceutische Ontwikkeling van Solvay Pharmaceuticals. Zijn onderzoeksgroep richt zich op geavanceerde technologie voor verbeterde toediening van medicijnen en heeft internationaal een prominente plaats verworven op dit terrein.
Zeker 600.000 patiënten gebruiken een inhalator die is bedacht door het team rondom Frijlink. ‘En het gaat richting de één miljoen. Het is mooi als je een product ontwikkelt dat patiënten kan helpen’, zegt Frijlink. De Novolizer is een poederinhalator, waarmee bijvoorbeeld astmapatiënten medicijnen in hun longen krijgen. Het geheim van de inhalator is de cycloon, een kamer waarin het geneesmiddel snel ronddraait, aangedreven door de inhalatiekracht van de patiënt.
Huibregtsenprijs nominatie prof.dr. Erik Frijlink
Frijlink leidt een internationaal consortium dat zoekt naar een universeel griepvaccin. Het onderzoek wordt uitgevoerd door twaalf internationale partners. De Europese Unie steunt het onderzoek met een subsidie van zes miljoen euro. Frijlink denkt dat het niet lang meer duurt voor er een vaccin is dat mensen beschermt tegen alle vormen van griep. Zo'n vaccin zou de jaarlijkse seizoensprik overbodig maken. Frijlink verwacht vooral veel van middelen die via een inhalator kunnen worden toegediend. Dat zou effectiever kunnen zijn dan een injectie.
Frijlink was genomineerd voor de Huibregtsenprijs 2016. Uit het juryrapport: "Het werk van Frijlink is exemplarisch voor baanbrekend onderzoek dat tegelijkertijd van groot belang is voor onze maatschappij. Het koppelt wetenschappelijke excellentie aan maatschappelijke relevantie en is tevens een van de weinige voorbeelden van hoe een vinding op een Nederlandse universiteit leidt tot een aanmerkelijke licentiestroom."
Eerder in het nieuws
2024
Nguyen,
K. T. T., Zillen, D., Lasorsa,
A., van der Wel, P. C. A., Frijlink, H.
W., & Hinrichs, W. L. J. (2024).
Combinations of arginine and pullulan reveal the selective
effect of stabilization mechanisms on different lyophilized
proteins. International Journal of
Pharmaceutics, 654, Article 123938. https://doi.org/10.1016/j.ijpharm.2024.123938
Janssen,
P. H. M., Fathollahi, S., Dickhoff, B. H. J., &
Frijlink, H. W. (2024). Critical review on the role of
excipient properties in pharmaceutical powder-to-tablet continuous
manufacturing. Expert Opinion on Drug
Delivery, 21(7), 1069-1079. https://doi.org/10.1080/17425247.2024.2384698
Heida,
R., Jacob Silva, P. H., Akkerman, R.,
Moser, J., de Vries-Idema, J., Bornet, A.,
Pawar, S., Stellacci, F., Frijlink, H. W.,
Huckriede, A. L. W., & Hinrichs, W. L. J.
(2024). Inhibition of influenza virus infection in mice by
pulmonary administration of a spray dried antiviral.
European journal of pharmaceutics and biopharmaceutics :
official journal of Arbeitsgemeinschaft fur Pharmazeutische
Verfahrenstechnik e.V, 204, Article 114507. https://doi.org/10.1016/j.ejpb.2024.114507
de
Jong, L., Luinstra, M., Aalbers, A. F., Wijma-Vos, A.
J., D’Angremont, E., van der Meulen, A. A. E., Rutgers, A. W.
F., Steenhuis, L., Hagedoorn, P., van Laar,
T., & Frijlink, H. W. (2024).
Therapeutic effect of an inhaled levodopa dry powder
formulation on off episodes in patients with Parkinson’s
disease. Therapeutic advances in neurological
disorders, 17. https://doi.org/10.1177/17562864241289207
2023
Otten,
A. T., van der Meulen, H. H., Steenhuis, M., Loeff, F.
C., Touw, D. J., Kosterink, J. G.
W., Frijlink, H. W., Rispens, T.,
Dijkstra, G., Visschedijk, M. C., &
Bourgonje, A. R. (2024). Clinical Validation of a
Capillary Blood Home-Based Self-Sampling Technique for Monitoring
of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations
in Patients With Inflammatory Bowel Disease.
Inflammatory Bowel Diseases, 30(3),
325–335. https://doi.org/10.1093/ibd/izad103
van
der Kooij, R. S., Beukema, M., Huckriede,
A. L. W., Zuidema, J., Steendam, R., Frijlink, H.
W., & Hinrichs, W. L. J. (2023). A
Single Injection with Sustained-Release Microspheres and a
Prime-Boost Injection of Bovine Serum Albumin Elicit the Same IgG
Antibody Response in Mice.
Pharmaceutics, 15(2), Article 676.
https://doi.org/10.3390/pharmaceutics15020676
Frijlink,
H., Lagarce, F., Touw, D., &
Woerdenbag, H. (2023). Biopharmaceutics. In P.
Le Brun, S. Crauste-Manciet, I. Krämer, J. Smith, & H.
Woerdenbag (Eds.), Practical Pharmaceutics: An International
Guideline for the Preparation, Care and Use of Medicinal Products,
Second Edition (pp. 67-91). Springer International Publishing
AG. https://doi.org/10.1007/978-3-031-20298-8_5
Ahmed,
A. A., Otten, A. T., Gareb, B., Huijmans,
J. E., Eissens, A. C., Rehman, A., Dijkstra,
G., Kosterink, J. G. W., Frijlink, H.
W., & Schellekens, R. C. A. (2023). Capsules with
Ileocolonic-Targeted Release of Vitamin B2, B3, and C (ColoVit)
Intended for Optimization of Gut Health: Development and Validation
of the Production Process.
Pharmaceutics, 15(5), Article 1354.
https://doi.org/10.3390/pharmaceutics15051354
Nugrahadi,
P. P., Hinrichs, W. L. J., Frijlink, H.
W., Schöneich, C., & Avanti, C. (2023).
Designing Formulation Strategies for Enhanced Stability of
Therapeutic Peptides in Aqueous Solutions: A Review.
Pharmaceutics, 15(3), Article
15030935. https://doi.org/10.3390/pharmaceutics15030935
Heida,
R., Akkerman, R., Silva, P. H. J., Lakerveld,
A., Ortiz, D., Bigogno, C., Gasbarri, M., Van Kasteren, P. B.,
Stellacci, F., Frijlink, H. W., Huckriede,
A., & Hinrichs, W. (2023).
Development of an inhalable antiviral powder formulation
against respiratory syncytial virus. Journal of
Controlled Release, 357(5), 264-273. https://doi.org/10.1016/j.jconrel.2023.03.059
Otten,
A. T., Peters, V., Barth,
I., Stevens, C. L., Bourgonje, A.
R., Frijlink, H. W., Harmsen, H. J.
M., Rehman, A., Campmans-Kuijpers, M. J.
E., & Dijkstra, G. (2023). Effects of
ileocolonic delivered vitamin B2, B3 and C
(ColoVit) or the Groningen anti-inflammatory diet on disease course
and microbiome of patients with Crohn's disease (VITA-GrAID study):
a protocol for a randomised and partially blinded trial.
BMJ Open, 13(3), Article e069654. https://doi.org/10.1136/bmjopen-2022-069654
Heida,
R., Frijlink, H. W., & Hinrichs, W.
L. J. (2023). Inhalation of vaccines and antiviral
drugs to fight respiratory virus infections: Reasons to prioritize
the pulmonary route of administration.
mBio, 14(5), Article e0129523. https://doi.org/10.1128/mbio.01295-23
Mahri,
S., Wilms, T., Hagedorm, P., Guichard, M. J., Vanvarenberg, K.,
Dumoulin, M., Frijlink, H., & Vanbever, R. (2023).
Nebulization of PEGylated recombinant human deoxyribonuclease
I using vibrating membrane nebulizers: A technical feasibility
study. European Journal of Pharmaceutical
Sciences, 189, Article 106522. https://doi.org/10.1016/j.ejps.2023.106522
Frijlink,
H. W., Eissens, A. C., van Goor,
H., Mulder, D. J., & Joles, J. A. (2023).
Oral dosage forms of a therapeutically active
acid-labile salt and methods and uses related thereto.
(Patent No. WO2023140729).
Heida,
R., Hagedoorn, P., Van Meel, M. C., Prins, R.,
Simonis, F., Akkerman, R., Frijlink, H.
W., Huckriede, A., de Boer,
A., & Hinrichs, W. (2023).
Performance Testing of a Homemade Aerosol Generator for
Pulmonary Administration of Dry Powder Formulations to Mice.
Pharmaceutics, 15(7), Article 1847.
https://doi.org/10.3390/pharmaceutics15071847
Nguyen,
K. T. T., Zillen, D., van Heijningen, F. F. M.,
van Bommel, K. J. C., van Ee, R. J., Frijlink, H.
W., & Hinrichs, W. L. J. (2023).
Surface Engineering Methods for Powder Bed Printed Tablets to
Optimize External Smoothness and Facilitate the Application of
Different Coatings. Pharmaceutics,
15(9), Article 2193. https://doi.org/10.3390/pharmaceutics15092193
2022
van
der Kooij, R. S., Steendam, R., Frijlink, H.
W., & Hinrichs, W. L. J. (2022). An
overview of the production methods for core-shell microspheres for
parenteral controlled drug delivery. European
journal of pharmaceutics and biopharmaceutics : official journal of
Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik
e.V, 170, 24-42. https://doi.org/10.1016/j.ejpb.2021.11.007
Jansen,
E. M., Frijlink, H. W., Hinrichs, W. L.
J., & Ruigrok, M. J. R. (2022). Are
inhaled mRNA vaccines safe and effective? A review of preclinical
studies. Expert Opinion on Drug
Delivery, 19(11), 1471-1485. https://doi.org/10.1080/17425247.2022.2131767
Heida,
R., Born, P. A., Tapia-Calle,
G., Frijlink, H. W., Salvati,
A., Huckriede, A. L. W., & Hinrichs,
W. L. J. (2022). Assessing the Immunomodulatory Effect
of Size on the Uptake and Immunogenicity of Influenza- and
Hepatitis B Subunit Vaccines In Vitro.
Pharmaceuticals, 15(7), Article 887.
https://doi.org/10.3390/ph15070887
Nguyen,
K. T. T., Heijningen, F. F. M., Zillen, D., van
Bommel, K. J. C., van Ee, R. J., Frijlink, H.
W., & Hinrichs, W. L. J. (2022).
Formulation of a 3D Printed Biopharmaceutical: The
Development of an Alkaline Phosphatase Containing Tablet with
Ileo-Colonic Release Profile to Treat Ulcerative Colitis.
Pharmaceutics, 14(10), Article 2179.
https://doi.org/10.3390/pharmaceutics14102179
Tian,
Y., Lee, J., van der Maaden, K., Bhide,
Y., de Vries-Idema, J. J., Akkerman,
R., O'Mahony, C., Jiskoot, W., Frijlink, H.
W., Huckriede, A. L. W., Hinrichs, W. L.
J., Bouwstra, J. A., & Beukema, M. (2022).
Intradermal Administration of Influenza Vaccine with
Trehalose and Pullulan-Based Dissolving Microneedle Arrays.
Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2022.01.033
Woerdenbag,
H. J., Visser, J. C., Leferink Op Reinink, M.
P. A. M., van Orsoy, R. R., Eissens, A. C.,
Hagedoorn, P., Dijkstra, H., Allersma, D. P., Ng, S. W.,
Smeets, O. S. N. M., & Frijlink, H. W. (2022).
Performance of Tablet Splitters, Crushers, and Grinders in
Relation to Personalised Medication with Tablets.
Pharmaceutics, 14(2), Article 320.
https://doi.org/10.3390/pharmaceutics14020320
Ruigrok,
M. J. R., Roest, M. A. P., Frijlink, H.
W., Olinga, P., Hinrichs, W. L.
J., & Melgert, B. N. (2022). RANKL
confers protection against cell death in precision-cut lung
slices. Frontiers in Physiology,
13, Article 1029697. https://doi.org/10.3389/fphys.2022.1029697
de
Reus, Y. A., Hagedoorn, P., Sturkenboom,
M. G. G., Grasmeijer, F., Bolhuis, M.
S., Sibum, I., Kerstjens, H. A. M.,
Frijlink, H. W., & Akkerman, O. W. (2022).
Tolerability and pharmacokinetic evaluation of inhaled dry
powder hydroxychloroquine in healthy volunteers.
PLoS ONE, 17(8), Article e0272034.
https://doi.org/10.1371/journal.pone.0272034
2021
Heida,
R., Hinrichs, W. L. J., & Frijlink,
H. W. (2022). Inhaled vaccine delivery in the combat
against respiratory viruses: A 2021 overview of recent developments
and implications for COVID-19. Expert review of
vaccines, 21(7), 957-974. https://doi.org/10.1080/14760584.2021.1903878
Larmené-Beld,
K., Wijnsma, R., Kuiper, A., van Berkel, S., Robben, H.,
Taxis, K., & Frijlink, H. (2022).
Science- and risk-based strategy to qualify prefillable
autoclavable syringes as primary packaging material.
European Journal of Hospital Pharmacy: Science and
Practice, 29(5), 248-254. https://doi.org/10.1136/ejhpharm-2020-002333
Broesder,
A., Bircan, S. Y., De Waard, A. B., Eissens, A.
C., Frijlink, H. W., & Hinrichs, W.
L. J. (2021). Formulation and in vitro evaluation of
pellets containing sulfasalazine and caffeine to verify
ileo-colonic drug delivery.
Pharmaceutics, 13(12), Article 1985.
https://doi.org/10.3390/pharmaceutics13121985
Ruigrok,
M. J. R., Frijlink, H. W., Melgert, B.
N., Olinga, P., & Hinrichs, W. L.
J. (2021). Gene therapy strategies for idiopathic
pulmonary fibrosis: recent advances, current challenges, and future
directions. Molecular Therapy - Methods &
Clinical Development, 20, 483-496. https://doi.org/10.1016/j.omtm.2021.01.003
Broesder,
A., Berends, J. M. E., Scheepers, S. M.,
Nguyen, D. N., Frijlink, H. W., & Hinrichs,
W. L. J. (2021). Ileo-Colon Targeting of the Poorly
Water-Soluble Drug Celecoxib Using a pH-Dependent Coating in
Combination with Self-Emulsifying Drug Delivery or Solid Dispersion
Systems. Pharmaceutics,
13(5). https://doi.org/10.3390/pharmaceutics13050731
Gareb,
B., Beugeling, M., Posthumus, S., Otten,
A. T., Dijkstra, G., Kosterink, J. G.
W., & Frijlink, H. W. (2021).
Infliximab formulation strategy for a stable ileo-colonic
targeted oral dosage form intended for the topical treatment of
inflammatory bowel disease. Journal of drug
delivery science and technology, 64, Article
102552. https://doi.org/10.1016/j.jddst.2021.102552
van
der Kooij, R. S., Steendam, R., Zuidema, J., Frijlink,
H. W., & Hinrichs, W. L. J. (2021).
Microfluidic Production of Polymeric Core-Shell Microspheres
for the Delayed Pulsatile Release of Bovine Serum Albumin as a
Model Antigen. Pharmaceutics,
13(11), Article 1854. https://doi.org/10.3390/pharmaceutics13111854
Zillen,
D., Beugeling, M., Hinrichs, W. L.
J., Frijlink, H. W., & Grasmeijer,
F. (2021). Natural and bioinspired excipients for dry
powder inhalation formulations. Current Opinion in
Colloid and Interface Science, 56, Article
101497. https://doi.org/10.1016/j.cocis.2021.101497
Ruigrok,
M. J. R., El Amasi, K. E. M., Leeming, D. J., Sand, J. M.
B., Frijlink, H. W., Hinrichs, W. L.
J., & Olinga, P. (2021). Silencing
Heat Shock Protein 47 (HSP47) in Fibrogenic Precision-Cut Lung
Slices: A Surprising Lack of Effects on Fibrogenesis?
Frontiers in Medicine, 8, Article
607962. https://doi.org/10.3389/fmed.2021.607962
2020
Heida,
R., Bhide, Y. C., Gasbarri, M., Kocabiyik,
Ö., Stellacci, F., Huckriede, A. L. W.,
Hinrichs, W. L. J., & Frijlink, H. W.
(2021). Advances in the development of entry inhibitors for
sialic-acid-targeting viruses. Drug Discovery
Today, 26(1), 122-137. https://doi.org/10.1016/j.drudis.2020.10.009
Akkerman-Nijland,
A. M., Akkerman, O. W., Grasmeijer,
F., Hagedoorn, P., Frijlink, H.
W., Rottier, B. L., Koppelman, G.
H., & Touw, D. J. (2021). The
pharmacokinetics of antibiotics in cystic fibrosis.
Expert Opinion on Drug Metabolism &
Toxicology, 17(1), 53-68. https://doi.org/10.1080/17425255.2021.1836157
Hagedoorn,
P., Bawary, W., Frijlink, H. W., &
Grasmeijer, F. (2020). A comparative analysis of
changes in pMDI drug dose delivery before and after detergent
coating using five antistatic valved holding chambers.
The Journal of Allergy and Clinical Immunology: In
Practice, 8(3), 1124-1125.e4. https://doi.org/10.1016/j.jaip.2019.09.021
Sibum,
I., Hagedoorn, P., Botterman, C. O.,
Frijlink, H. W., & Grasmeijer, F. (2020).
Automated Filling Equipment Allows Increase in the Maximum
Dose to Be Filled in the Cyclops(R)High Dose Dry Powder Inhalation
Device While Maintaining Dispersibility.
Pharmaceutics, 12(7), 1-14. Article
645. https://doi.org/10.3390/pharmaceutics12070645
Akkerman-Nijland,
A. M., Grasmeijer, F., Kerstjens, H. A.
M., Frijlink, H. W., van der Vaart,
H., Vonk, J. M., Hagedoorn,
P., Rottier, B. L., Koppelman, G.
H., & Akkerman, O. W. (2020).
Colistin dry powder inhalation with the Twincer (TM): An
effective and more patient friendly alternative to
nebulization. PLoS ONE,
15(9), Article e0239658. https://doi.org/10.1371/journal.pone.0239658
Hagedoorn,
P., Grasmeijer, F., Bawari, W., Frijlink,
H. W., & Grasmeijer, F. (2020).
Comparing five antistatic valved holding chambers: How
antistatic are they really? European Respiratory
Journal, 56. https://doi.org/10.1183/13993003.congress-2020.3177
Gareb,
B., Dijkstra, G., Kosterink, J. G.
W., & Frijlink, H. W. (2020). De
ontwikkeling van budesonidetabletten met nulde-orde-afgifte voor de
behandeling van ileo-colonische inflammatoire darmziekten en
vergelijking met huidige, commerciële preparaten.
Pharmaceutisch Weekblad, 155(6),
29-36. https://www.npfo.nl/artikel/de-ontwikkeling-van-budesonidetabletten-met-nulde-orde-afgifte-voor-de-behandeling-van-ileo
Tian,
Y., Bhide, Y. C., Woerdenbag, H.
J., Huckriede, A. L. W., Frijlink, H.
W., Hinrichs, W. L. J., & Visser, J.
C. (2020). Development of an Orodispersible Film
Containing Stabilized Influenza Vaccine.
Pharmaceutics, 12(3), Article 245.
https://doi.org/10.3390/pharmaceutics12030245
Weerts,
Z. Z. R. M., Masclee, A. A. M., Witteman, B. J. M., Clemens, C. H.
M., Winkens, B., Brouwers, J. R. B. J., Frijlink, H.
W., Muris, J. W. M., De Wit, N. J., Essers, B. A. B., Tack,
J., Snijkers, J. T. W., Bours, A. M. H., de Ruiter-van der Ploeg,
A. S., Jonkers, D. M. A. E., & Keszthelyi, D. (2020).
Efficacy and Safety of Peppermint Oil in a Randomized,
Double-Blind Trial of Patients With Irritable Bowel
Syndrome. Gastroenterology,
158(1), 123-136. Article 158. https://doi.org/10.1053/j.gastro.2019.08.026
Akkerman-Nijland,
A. M., Yousofi, M., Rottier, B. L., Van
der Vaart, H., Burgerhof, J. G. M.,
Frijlink, H. W., Touw, D. J., Koppelman,
G. H., & Akkerman, O. W. (2020).
Eradication of Pseudomonas aeruginosa in cystic fibrosis
patients with inhalation of dry powder tobramycin.
Therapeutic advances in respiratory disease,
14, Article 1753466620905279. https://doi.org/10.1177/1753466620905279
Pleguezuelos,
O., Dille, J., de Groen, S., Oftung, F.,
Niesters, H. G. M., Islam, M. A., Naess, L. M., Hungnes, O.,
Aldarij, N., Idema, D. L., Perez, A. F., James, E., Frijlink,
H. W., Stoloff, G., Groeneveld, P., & Hak,
E. (2020). Immunogenicity, Safety, and Efficacy of a
Standalone Universal Influenza Vaccine, FLU-v, in Healthy
Adults. Annals of Internal Medicine,
172(7), 453-462. https://doi.org/10.7326/M19-0735
Nguyen,
K. T. T., Frijlink, H. W., &
Hinrichs, W. L. J. (2020). Inhomogeneous Distribution
of Components in Solid Protein Pharmaceuticals: Origins,
Consequences, Analysis, and Resolutions. Journal
of Pharmaceutical Sciences, 109(1), 134-153.
https://doi.org/10.1016/j.xphs.2019.10.010
Ruigrok,
M., El-Amasi, K., Frijlink, H. W.,
Hinrichs, W., & Olinga, P. (2020).
Knockdown of heat shock protein 47 (HSP47) and its
effects on fibrogenesis. Poster session presented at
Keystone Symposia on Fibrosis and Tissue Repair, Victoria,
Canada.
Sibum,
I., Grasmeijer, F., Hagedoorn, P.,
& Frijlink, H. W. (2020). Optimisation of an
isoniazid dry powder formulation for pulmonary
administration. Journal of aerosol medicine and
pulmonary drug delivery, 33(2), A2-A2.
Broesder,
A., Woerdenbag, H. J., Prins, G.
H., Nguyen, D. N., Frijlink, H. W., &
Hinrichs, W. L. J. (2020). pH-dependent ileocolonic
drug delivery, part I: in vitro and clinical evaluation of novel
systems. Drug Discovery Today,
25(8), 1362-1373. https://doi.org/10.1016/j.drudis.2020.06.011
Broesder,
A., Kosta, A.-M. M. A. C., Woerdenbag, H.
J., Nguyen, D. N., Frijlink, H. W., &
Hinrichs, W. L. J. (2020). pH-dependent ileocolonic
drug delivery, part II: Preclinical evaluation of novel drugs and
novel excipients. Drug Discovery
Today, 25(8), 1374-1388. https://doi.org/10.1016/j.drudis.2020.06.012
Larmene-Beld,
K. H. M., van Berkel, S., Wijnsma, R., Taxis,
K., & Frijlink, H. W. (2020).
Prefilled Cyclic Olefin Sterilized Syringes of Norepinephrine
Injection Solution Do Not Need to Be Stabilized by
Antioxidants. Aaps pharmscitech,
21(7), 247. Article 247. https://doi.org/10.1208/s12249-020-01784-z
Hagedoorn,
P., Bawary, W., Frijlink, H. W., &
Grasmeijer, F. (2020). Relative lung dose from
antistatic valved holding chambers Reply. The
Journal of Allergy and Clinical Immunology: In
Practice, 8(3), 1166-1167. https://doi.org/10.1016/j.jaip.2019.11.023
Gareb,
B., Otten, A. T., Frijlink, H.
W., Dijkstra, G., & Kosterink, J. G.
W. (2020). Review: Local Tumor Necrosis Factor-alpha
Inhibition in Inflammatory Bowel Disease.
Pharmaceutics, 12(6), 1-31. Article
539. https://doi.org/10.3390/pharmaceutics12060539
Gerritsen,
J., Bloemers, J., van Rooij, K., de Leede, L., van der Geest,
R., Frijlink, H. W., Koppeschaar, H. P. F., Olivier,
B., & Tuiten, A. (2020). The Effect of Food on the
Pharmacokinetics of Buspirone After Single Administration of a
Sublingual Testosterone and Oral Buspirone Combination Tablet in
Healthy Female Subjects. Sexual
medicine, 8(2), 186-194. https://doi.org/10.1016/j.esxm.2020.01.005
2019
Busscher,
H. J., Woudstra, W., van Kooten, T.
G., Jutte, P., Shi, L., Liu, J.,
Hinrichs, W. L. J., Frijlink, H. W., Shi, R.,
Liu, J., Parvizi, J., Kates, S., Rotello, V. M., Schaer, T. P.,
Williams, D., Grainger, D. W., & van der Mei, H.
C. (2020). Accepting higher morbidity in exchange for
sacrificing fewer animals in studies developing novel
infection-control strategies.
Biomaterials, 232, Article 119737.
https://doi.org/10.1016/j.biomaterials.2019.119737
Sibum,
I., Hagedoorn, P., Kluitman, M. P. G., Kloezen,
M., Frijlink, H. W., & Grasmeijer, F.
(2020). Dispersibility and Storage Stability Optimization of
High Dose Isoniazid Dry Powder Inhalation Formulations with
L-Leucine or Trileucine.
Pharmaceutics, 12(1), Article 24. https://doi.org/10.3390/pharmaceutics12010024
Yska,
J. P., Wanders, J. T. M., Odigie, B., Apers, J. A., Emous,
M., Totté, E. R. E., Boerma, E. C., Ubels,
F. L., Woerdenbag, H. J., Frijlink, H.
W., Wilffert, B., & Van Roon, E.
N. (2020). Effect of Roux-en-Y gastric bypass on the
bioavailability of metoprolol from immediate and controlled release
tablets: A single oral dose study before and after surgery.
European Journal of Hospital Pharmacy: Science and
Practice, 27(E1), e19–e24. https://doi.org/10.1136/ejhpharm-2018-001804
Boudewijn,
I. M., Lan, A., Faiz, A., Cox, C. A.,
Brouwer, S., Schokker, S., Vroegop, S. J., Nawijn, M.
C., Woodruff, P. G., Christenson, S. A., Hagedoorn,
P., Frijlink, H. W., Choy, D. F.,
Brouwer, U., Wisman, M., Postma, D.
S., Fingleton, J., Beasley, R., van den Berge,
M., & Guryev, V. (2020). Nasal gene
expression changes with inhaled corticosteroid treatment in
asthma. Allergy, 75(1),
191-194. https://doi.org/10.1111/all.13952
Yska,
J. P., Punter, R. J., Woerdenbag, H. J., Emous,
M., Frijlink, H. W., Wilffert,
B., & Van Roon, E. N. (2019). A
gastrointestinal simulation system for dissolution of oral solid
dosage forms before and after Roux-en-Y gastric bypass.
European Journal of Hospital Pharmacy: Science and
Practice, 26(3), 152-156. https://doi.org/10.1136/ejhpharm-2017-001360
Cox,
C. A., Boudewijn, I. M., Vroegop, S. J.,
Schokker, S., Lexmond, A. J., Frijlink, H.
W., Hagedoorn, P., Vonk, J.
M., Farenhorst, M. P., ten Hacken, N. H.
T., Kerstjens, H. A. M., & van den
Berge, M. (2019). Associations of AMP and adenosine
induced dyspnea sensation to large and small airways dysfunction in
asthma. BMC Pulmonary Medicine,
19(1), Article 23. https://doi.org/10.1186/s12890-019-0783-0
Larmené-Beld,
K. H. M., Frijlink, H. W., & Taxis,
K. (2019). A systematic review and meta-analysis of
microbial contamination of parenteral medication prepared in a
clinical versus pharmacy environment. European
Journal of Clinical Pharmacology, 75(5),
609-617. https://doi.org/10.1007/s00228-019-02631-2
Sibum,
I., Hagedoorn, P., Frijlink, H.
W., & Grasmeijer, F. (2019).
Characterization and Formulation of Isoniazid for High-Dose
Dry Powder Inhalation. Pharmaceutics,
11(5), Article 233. https://doi.org/10.3390/pharmaceutics11050233
Janssen,
R., Wouters, E. F. M., Janssens, W., Daamen, W. F.,
Hagedoorn, P., de Wit, H. A. J. M., Serre, J.,
Gayan-Ramirez, G., Franssen, F. M. E., Reynaert, N. L., von der
Thusen, J. H., & Frijlink, H. W. (2019).
Copper-Heparin Inhalation Therapy To Repair Emphysema: A
Scientific Rationale. International Journal of
Chronic Obstructive Pulmonary Disease, 14,
2587-2602. https://doi.org/10.2147/COPD.S228411
Beugeling,
M., Amssoms, K., Cox, F., De Clerck, B., Van Gulck, E.,
Verwoerd, J., Kraus, G., Roymans, D., Baert, L., Frijlink, H.
W., & Hinrichs, W. (2019).
Development of a Stable Respiratory Syncytial Virus
Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a
Delayed Release in Mice: A Proof of Concept Study.
Pharmaceutics, 11(10), Article 510.
https://doi.org/10.3390/pharmaceutics11100510
Sibum,
I., Grasmeijer, F., Hagedoorn, P.,
& Frijlink, H. W. (2019). Formulating Amikacin for
dry powder inhalation. Journal of aerosol medicine
and pulmonary drug delivery, 32(2), A7-A7. https://doi.org/10.1089/jamp.2019.ab01.abstracts
Luinstra,
M., Isufi, V., de Jong, L., Rutgers, A. W. F.,
Hagedoorn, P., Puttenstein, J., van Laar,
T., & Frijlink, H. W. (2019).
Learning from Parkinson's patients: Usability of the Cyclops
dry powder inhaler. International Journal of
Pharmaceutics, 567, 118493. Article 118493. https://doi.org/10.1016/j.ijpharm.2019.118493
Tian,
Y., Orlu, M., Woerdenbag, H. J., Scarpa, M.,
Kiefer, O., Kottke, D., Sjoholm, E., Oblom, H., Sandler, N.,
Hinrichs, W. L. J., Frijlink, H. W.,
Breitkreutz, J., & Visser, J. C. (2019).
Oromucosal films: from patient centricity to production by
printing techniques. Expert Opinion on Drug
Delivery, 16(9), 981-993. https://doi.org/10.1080/17425247.2019.1652595
Beugeling,
M., Born, P., Amssoms, K., De Clerck, B., Van
Gulck, E., Frijlink, H. W., Grasmeijer, N., Kraus, G.,
Baert, L., & Hinrichs, W. (2019).
Ovalbumin-Containing Core-Shell Implants Suitable to
Obtain a Delayed IgG1 Antibody Response in Mice. Poster
session presented at AAPS PharmSci 360, San Antonio, United
States.
Luinstra,
M., Rutgers, W., van Laar, T.,
Grasmeijer, F., Begeman, A., Isufi, V., Steenhuis, L.,
Hagedoorn, P., de Boer, A., &
Frijlink, H. W. (2019). Pharmacokinetics and
tolerability of inhaled levodopa from a new dry-powder inhaler in
patients with Parkinson's disease. Therapeutic
advances in chronic disease, 10. https://doi.org/10.1177/2040622319857617
Tian,
Y., Visser, C., Woerdenbag,
H., Frijlink, H. W., & Hinrichs,
W. (2019). Printing biopharmaceuticals onto
orodispersible films. Poster session presented at AAPS
PharmSci 360, San Antonio, United States.
Tomar,
J., Tonnis, W. F., Patil, H. P., de Boer, A. H.,
Hagedoorn, P., Vanbever, R., Frijlink, H.
W., & Hinrichs, W. L. J. (2019).
Pulmonary immunization: deposition site is of minor relevance
for influenza vaccination but deep lung deposition is crucial for
hepatitis B vaccination. Acta Pharmaceutica Sinica
B, 9(6), 1231-1240. https://doi.org/10.1016/j.apsb.2019.05.003
Beugeling,
M., De Zee, J., Woerdenbag, H. J.,
Frijlink, H. W., Wilschut, J. C., &
Hinrichs, W. L. J. (2019). Respiratory syncytial virus
subunit vaccines based on the viral envelope glycoproteins intended
for pregnant women and the elderly. Expert review
of vaccines, 18(9), 935-950. https://doi.org/10.1080/14760584.2019.1657013
van
Dijk, F., Teekamp, N., Post, E., Schuppan, D.,
Kim, Y. O., Zuidema, J., Steendam, R., Klose, M. H. M.,
Meier-Menches, S. M., Casini, A., Horvatovich, P. L.,
Sijbrandi, N. J., Frijlink, H. W., Hinrichs, W.
L. J., Poelstra, K., Beljaars,
L., & Olinga, P. (2019). The
antifibrotic potential of a sustained release formulation of a PDGF
beta-receptor targeted rho kinase inhibitor.
Journal of Controlled Release, 296,
250-257. https://doi.org/10.1016/j.jconrel.2018.12.039
Bloemers,
J., Gerritsen, J., van Rooij, K., de Leede, L., van der Geest,
R., Frijlink, H. W., Koppeschaar, H. P. F., Olivier,
B., & Tuiten, A. (2019). The Effect of Food on the
Pharmacokinetics of Sildenafil after Single Administration of a
Sublingual Testosterone and Oral Sildenafil Combination Tablet in
Healthy Female Subjects. Journal of Sexual
Medicine, 16(9), 1433-1443. https://doi.org/10.1016/j.jsxm.2019.06.015
Ruigrok,
M., Tomar, J., Frijlink, H. W., Melgert,
B., Hinrichs, W., & Olinga, P.
(2019). The effects of oxygen concentration on cell death,
anti-oxidant transcription, acute inflammation, and cell
proliferation in precision-cut lung slices.
Scientific Reports, 9(1), Article
16239. https://doi.org/10.1038/s41598-019-52813-2
Beugeling,
M., Grasmeijer, N., Born, P., van der Meulen,
M., Kooij, van der, R., Schwengle, K., Baert, L.,
Amssoms, K., Frijlink, H. W., & Hinrichs,
W. (2019). The Mechanism Behind the Biphasic
Pulsatile Drug Release from Physically Mixed
Poly(DL-Lactic(-Co-Glycolic) Acid)-Based Compacts.
Poster session presented at AAPS PharmSci 360, San Antonio, United
States.
Gareb,
B., Posthumus, S., Beugeling, M., Koopmans,
P., Touw, D. J., Dijkstra, G.,
Kosterink, J. G. W., & Frijlink, H. W.
(2019). Towards the Oral Treatment of Ileo-Colonic
Inflammatory Bowel Disease with Infliximab Tablets: Development and
Validation of the Production Process.
Pharmaceutics, 11(9), Article 428.
https://doi.org/10.3390/pharmaceutics11090428
Murti,
Y. B., Hartini, Y. S., Hinrichs, W. L. J.,
Frijlink, H. W., & Setyaningsih, D. (2019). UV-Vis
spectroscopy to enable determination of the dissolution behavior of
solid dispersions containing curcumin and piperine.
Journal of Young Pharmacists, 11(1),
26-30. https://doi.org/10.5530/jyp.2019.11.6
Frijlink,
H. W. (2019). Wisselen van
medicijnen.
2018
Gareb,
B., Dijkstra, G., Kosterink, J. G.
W., & Frijlink, H. W. (2019).
Development of novel zero-order release budesonide tablets
for the treatment of ileo-colonic inflammatory bowel disease and
comparison with formulations currently used in clinical
practice. International Journal of
Pharmaceutics, 554, 366-375. https://doi.org/10.1016/j.ijpharm.2018.11.019
Grasmeijer,
N., Tiraboschi, V., Woerdenbag, H. J., Frijlink,
H. W., & Hinrichs, W. L. J. (2019).
Identifying critical process steps to protein stability
during spray drying using a vibrating mesh or a two-fluid
nozzle. European Journal of Pharmaceutical
Sciences, 128, 152-157. https://doi.org/10.1016/j.ejps.2018.11.027
Tomar,
J., Patil, H. P., Bracho, G., Tonnis, W. F., Frijlink, H.
W., Petrovsky, N., Vanbever, R., Huckriede,
A., & Hinrichs, W. L. J. (2018).
Advax augments B and T cell responses upon influenza
vaccination via the respiratory tract and enables complete
protection of mice against lethal influenza virus challenge.
Journal of Controlled Release, 288,
199-211. https://doi.org/10.1016/j.jconrel.2018.09.006
Weerts,
Z. Z. R. M., Keszthelyi, D., Vork, L., Aendekerk, N. C. P.,
Frijlink, H. W., Brouwers, J. R. B. J., Neef, C., Jonkers,
D. M. A. E., & Masclee, A. A. M. (2018). A Novel
Ileocolonic Release Peppermint Oil Capsule for Treatment of
Irritable Bowel Syndrome: A Phase I Study in Healthy
Volunteers. Advances in therapy,
35(11), 1965-1978. https://doi.org/10.1007/s12325-018-0802-1
Sibum,
I., Hagedoorn, P., de Boer, A.
H., Frijlink, H. W., & Grasmeijer,
F. (2018). Challenges for pulmonary delivery of high
powder doses. International Journal of
Pharmaceutics, 548(1), 325-336. https://doi.org/10.1016/j.ijpharm.2018.07.008
Akkerman,
O. W., Grasmeijer, F., de Lange, W. C.
M., Kerstjens, H. A. M., de Vries, G.,
Bolhuis, M. S., Alffenaar, J.-W.,
Frijlink, H. W., Smith, G., Gajraj, R., de Zwaan, R.,
Hagedoorn, P., Dedicoat, M., van Soolingen, D., &
van der Werf, T. S. (2018). Cross border, highly
individualised treatment of a patient with challenging extensively
drug-resistant tuberculosis. European Respiratory
Journal, 51(3), Article 1702490. https://doi.org/10.1183/13993003.02490-2017
Kanojia,
G., Raeven, R. H. M., van der Maas, L., Bindels, T. H. E., van
Riet, E., Metz, B., Soema, P. C., Ten Have, R., Frijlink, H.
W., Amorij, J.-P., & Kersten, G. F. A. (2018).
Development of a thermostable spray dried outer membrane
vesicle pertussis vaccine for pulmonary immunization.
Journal of controlled release : official journal of the
Controlled Release Society, 286, 167-178. https://doi.org/10.1016/j.jconrel.2018.07.035
Tuiten,
A., van Rooij, K., Bloemers, J., Eisenegger, C., van Honk, J.,
Kessels, R., Kingsberg, S., Derogatis, L. R., de Leede, L.,
Gerritsen, J., Koppeschaar, H. P. F., Olivier, B., Everaerd,
W., Frijlink, H. W., Höhle, D., de Lange, R. P.
J., Böcker, K. B. E., & Pfaus, J. G. (2018).
Efficacy and safety of on-demand use of 2 treatments designed
for different etiologies of female sexual interest/arousal
disorder: 3 Randomized Clinical Trials. Journal of
Sexual Medicine, 15(2), 201-216. https://doi.org/10.1016/j.jsxm.2017.11.226
Kauppinen,
A., Broekhuis, J., Grasmeijer, N., Tonnis, W., Ketolainen,
J., Frijlink, H. W., & Hinrichs, W. L.
J. (2018). Efficient production of solid dispersions
by spray drying solutions of high solid content using a 3-fluid
nozzle. European Journal of Pharmaceutics and
Biopharmaceutics, 123, 50-58. https://doi.org/10.1016/j.ejpb.2017.11.009
Sibum,
I., Grasmeijer, F., Hagedoorn, P.,
& Frijlink, H. W. (2018). FORMULATING ISONIAZID
FOR DRY POWDER INHALATION BY SPRAY DRYING. Journal
of aerosol medicine and pulmonary drug delivery,
31(2), A2-A2.
Broesder,
A., Teekamp, N., van Dijk, F., Beljaars,
E., Hinrichs, W., Poelstra,
K., Frijlink, H. W., & Olinga,
P. (2018). Formulation of biodegradable
microspheres for the sustained release of PDGFβ-receptor
directed HSA targeted to fibrotic tissue. Poster
session presented at 11th World Meeting on Pharmaceutics,
Biopharmaceutics and Pharmaceutical Technology, Granada,
Spain.
Tuiten,
A., Michiels, F., Böcker, K. B., Höhle, D., van Honk, J.,
de Lange, R. P., van Rooij, K., Kessels, R., Bloemers, J.,
Gerritsen, J., Janssen, P., de Leede, L., Meyer, J.-J., Everaerd,
W., Frijlink, H. W., Koppeschaar, H. P., Olivier, B.,
& Pfaus, J. G. (2018). Genotype scores predict drug
efficacy in subtypes of female sexual interest/arousal disorder: A
double-blind, randomized, placebo-controlled cross-over
trial. Women's health (London,
England), 14. https://doi.org/10.1177/1745506518788970
Frijlink,
H. W. (2018). Moeiteloos inhaleren.
New scientist, (Special 'Engineering in
Groningen'), 28-29.
Tian,
Y., Visser, J. C., Klever, J. S.,
Woerdenbag, H. J., Frijlink, H. W., &
Hinrichs, W. L. J. (2018). Orodispersible films based
on blends of trehalose and pullulan for protein delivery.
European Journal of Pharmaceutics and
Biopharmaceutics, 133, 104-111. https://doi.org/10.1016/j.ejpb.2018.09.016
Amssoms,
K., Born, P. A., Beugeling, M., De
Clerck, B., Van Gulck, E., Hinrichs, W. L. J.,
Frijlink, H. W., Grasmeijer, N., Kraus, G., Sutmuller, R.,
Simmen, K., & Baert, L. (2018). Ovalbumin-containing
core-shell implants suitable to obtain a delayed IgG1 antibody
response in support of a biphasic pulsatile release profile in
mice. PLoS ONE, 13(8),
e0202961. Article 0202961. https://doi.org/10.1371/journal.pone.0202961
Tomar,
J., Biel, C., de Haan, C. A. M., Rottier, P. J. M.,
Petrovsky, N., Frijlink, H. W., Huckriede,
A., Hinrichs, W. L. J., & Peeters, B.
(2018). Passive inhalation of dry powder influenza vaccine
formulations completely protects chickens against H5N1 lethal viral
challenge. European Journal of Pharmaceutics and
Biopharmaceutics, 133, 85-95. https://doi.org/10.1016/j.ejpb.2018.10.008
Luinstra,
M., Rutgers, A. W. F., Vroegop, S. J., Begeman, A.,
Lexmond, A. J., Grasmeijer, F.,
Hagedoorn, P., de Boer, A. H., &
Frijlink, H. W. (2018). PHARMACOKINETIC EVALUATION AND
TOLERABILITY OF INHALED DRY POWDER LEVODOPA IN PARKINSON'S DISEASE
PATIENTS. Journal of aerosol medicine and
pulmonary drug delivery, 31(2), A9-A9.
Gafar,
F., Boudewijn, I. M., Cox, C. A., Vonk,
J. M., Schokker, S., Lexmond, A. J.,
Frijlink, H. W., Hagedoorn, P., Postma,
D. S., & van den Berge, M. (2018).
Predictors of clinical response to extrafine and
non-extrafine particle inhaled corticosteroids in smokers and
ex-smokers with asthma. Respiratory
Research, 19(1), Article 256. https://doi.org/10.1186/s12931-018-0961-2
Tian,
Y., Visser, J. C., Frijlink, H.
W., & Woerdenbag, H. (2018). Pullulan
and trehalose based films for protein delivery in the oral
cavity. Journal of Hepatology.
Bhide,
Y., Tomar, J., Dong, W., de Vries-Idema,
J., Frijlink, H. W., Huckriede,
A., & Hinrichs, W. L. J. (2018).
Pulmonary delivery of influenza vaccine formulations in
cotton rats: Site of deposition plays a minor role in the
protective efficacy against clinical isolate o H1N1pdm
virus. Drug Delivery, 25(1),
533-545. https://doi.org/10.1080/10717544.2018.1435748
2017
Lexmond,
A. J., Boudewijn, I. M., Hagedoorn, P.,
Schokker, S., Cox, C. A., Vonk, J.
M., ten Hacken, N. H. T., Frijlink, H.
W., Vroegop, S. J., & van den Berge,
M. (2018). Bronchial Provocation Testing Can Be
Improved by Using Dry Powder Adenosine Instead of Nebulized
Adenosine Monophosphate. American Journal of
Respiratory and Critical Care Medicine,
197(3), 391-394. https://doi.org/10.1164/rccm.201704-0715LE
van
Dijk, F., Teekamp, N., Beljaars, L.,
Post, E., Zuidema, J., Steendam, R., Kim, Y. O.,
Frijlink, H. W., Schuppand, D., Poelstra,
K., Hinrichs, W. L. J., & Olinga,
P. (2018). Pharmacokinetics of a sustained release
formulation of PDGFβ-receptor directed carrier proteins to
target the fibrotic liver. Journal of Controlled
Release, 269, 258-265. https://doi.org/10.1016/j.jconrel.2017.11.029
| Laatst gewijzigd: | 04 september 2024 15:10 |
View this page in: English